Company Profiles

driven by the PitchBook Platform

Adaptive Biotechnologies

Description

Developer of immuno-sequencing diagnostics. The company offers a technology based on sequencing to provide analysis of the T- and B-cell repertoire in order to support the fights against cancer, auto-immune and other infectious diseases.

2009

Founded

PRIVATE

Status

51-200

Employees

Series F

Latest Deal Type

$195M

Latest Deal Amount

$420M

Total Amount Raised

Description

Developer of immuno-sequencing diagnostics. The company offers a technology based on sequencing to provide analysis of the T- and B-cell repertoire in order to support the fights against cancer, auto-immune and other infectious diseases.

Website:

www.adaptivebiotech.com

Formerly Known As

Adaptive TCR

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Delivery

Primary Office

1551 Eastlake Avenue East Suite 200 Seattle, WA 98102United States +1 (206) 659-0067
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Adaptive Biotechnologies's full profile, request a free trial.

Adaptive Biotechnologies Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Adaptive Biotechnologies Investors (15)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Alexandria Real Estate EquitiesReal EstateMinority000 0000000 0000
Angel InvestorsVenture CapitalMinority000 0000000 0000
Ares CapitalPE/BuyoutMinority000 0000000 0000
BD BiosciencesCorporationMinority000 0000000 0000
Casdin CapitalVenture CapitalMinority000 0000000 0000
Alexandria Real Estate Equities Real Estate
Angel Investors Venture Capital
Ares Capital PE/Buyout
BD Biosciences Corporation
Casdin Capital Venture Capital

Adaptive Biotechnologies Executive Team (14)

NameTitleBoard
Seat
Contact
Info
Kathleen Determann JDVice President & General Counsel
Ilan Kirsch MDSenior Vice President, Translational Medicine
Cindy Desmarais Ph.DVice President, Client Relations
Danielle ScelfoVice President, Government Affairs & Reimbursement
Andy AmentVice President, Operations
Kathleen Determann JD Vice President & General Counsel
Ilan Kirsch MD Senior Vice President, Translational Medicine
Cindy Desmarais Ph.D Vice President, Client Relations
Danielle Scelfo Vice President, Government Affairs & Reimbursement
Andy Ament Vice President, Operations

Adaptive Biotechnologies Board Members (6)

NameRepresentingRoleSinceContact
Info
Andris ZoltnersSelfBoard Member000 0000
Arnold Levine Ph.DSelfBoard Member000 0000
John StuelpnagelSelfBoard Member000 0000
Lee Huntsman Ph.DSelfBoard Member000 0000
Robert Hershberg Ph.DCelgeneChief Scientific Officer000 0000
Andris Zoltners Board Member Self
Arnold Levine Ph.D Board Member Self
John Stuelpnagel Board Member Self
Lee Huntsman Ph.D Board Member Self
Robert Hershberg Ph.D Chief Scientific Officer Celgene
Request full access to PitchBook